Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): Analysis of phase I metabolism with hepatocytes of six species including human

Toxicology

Volumn 206, Issue 1, 2005, Pages 75-89

  Carmo, Helena ^a   Hengstler, Jan G ^b   Boer, Douwe De ^c   Ringel, Michael ^b   Remião, Fernando ^a   Carvalho, Félix ^a   Fernandes, Eduarda ^a   Reys, Lesseps A Dos ^c   Oesch, Franz ^b   Bastos, Maria De Lourdes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Institute of Sports Portugal   (Portugal)

Author keywords

2C B; Cryopreserved hepatocytes; Designer drugs of abuse; Hepatic metabolism

Indexed keywords

2 (4 BROMO 2,5 DIMETHOXYPHENYL)ETHANOL; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; 4 BROMO 2,5 DIMETHOXYPHENYLACETIC ACID; ADENOSINE TRIPHOSPHATE; ALCOHOL DERIVATIVE; HOMOVERATRYLAMINE; PHENYLACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; BIOASSAY; CELL METABOLISM; CONTROLLED STUDY; DEAMINATION; DEMETHYLATION; DISEASE PREDISPOSITION; DOG; DONOR; EXAMINATION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL; MALE; MONKEY; MOUSE; NONHUMAN; OBSERVATION; OXIDATION; PRIORITY JOURNAL; RABBIT; RAT; SPECIES COMPARISON;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ADENOSINE TRIPHOSPHATE; ANIMALS; CELLS, CULTURED; DEAMINATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED STRAINS; MIDDLE AGED; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; STREET DRUGS;

CANIS FAMILIARIS; NEXUS; ORYCTOLAGUS CUNICULUS;

EID: 10044284034     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2004.07.004     Document Type: Article

References (43)

1. M.V. Bach, R.T. Coutts, and G.B. Baker Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives Xenobiotica 29 1999 719 732
2. R.J. Baldessarini Symposium: Behavior modification by drugs I. Pharmacology of the amphetamines Pediatrics 49 1972 694 701
3. J. Caldwell The metabolism of amphetamines and related stimulants in animals and man J. Caldwell Amphetamines and Related Stimulants: Chemical, Biological, Clinical, and Sociological Aspects 1980 CRC Press Boca Raton pp. 29-46
4. H. Carmo, J.G. Hengstler, D. de Boer, M. Ringel, F. Carvalho, E. Fernandes, F. Remião, L.A. Reys, F. Oesch, and M.L. Bastos Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse Naunyn Schmiedeberg's Arch. Pharmacol. 369 2004 198 205
5. M.I. Colado, J.L. Williams, and A.R. Green The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype Br. J. Pharmacol. 115 1995 1281 1289
6. D. de Boer, and I. Bosman A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs Pharm. World Sci. 26 2004 110 113
7. D. de Boer, M.J. Gijzels, I.J. Bosman, and R.A.A. Maes More data about the new psychoactive drug 2C-B J. Anal. Toxicol. 23 1999 227 228
8. D. de Boer, L.A. Reys, N. Pylon, M. Gijzels, I.J. Bosman, and R.A.A. Maes Preliminary results on the urinary excretion of 2C-B (4-bromo-2 5-dimethoxyphenethylamine) and its metabolites in humans Br. J. Pharmacol. 127 1999 41
9. L. Demisch, and N. Seiler Oxidative metabolism of mescaline in the central nervous system - V. In vitro deamination of mescaline to 3,4,5-trimethoxy-benzoic acid Biochem. Pharmacol. 24 1975 575 580
10. L.G. Dring, R.L. Smith, and R.T. Williams The metabolic fate of amphetamine in man and other species Biochem. J. 116 1970 425 435
11. B.C. Foster, D.L. Litster, H.S. Buttar, B. Dawson, and J. Zamecnik Biotransformation and urinary excretion of 4-substituted amphetamines in pregnant mice Biopharm. Drug Dispos. 14 1993 709 719
12. B.C. Foster, D.L. Wilson, T.D. Cyr, J. Moffatt, and H.S. Buttar The influence of pregnancy on the biotransformation and urinary excretion of methoxyphenamine in mice Biopharm. Drug Dispos. 16 1995 1 11
13. G. Fritz, J.G. Hengstler, and B. Kaina High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines Cancer Res. 57 1997 454 460
14. C. Giroud, M. Augsburger, L. Rivier, P. Mangin, F. Sadeghipour, E. Varesio, J.L. Veuthey, and P. Kamalaprija 2C-B: a new psychoactive phenylethylamine recently discovered in ecstasy tablets sold on the Swiss black market J. Anal. Toxicol. 22 1998 345 354
15. C. Giroud, M. Augsburger, F. Sadeghipour, E. Varesio, J.L. Veuthey, and L. Rivier Ecstasy-the situation in the French part of Switzerland: composition of the seized drugs, analysis of biological specimens and short review of its pharmacology and toxicology Praxis 86 1997 510 523
16. R.A. Glennon, M. Titeler, and R.A. Lyon A preliminary investigation of the psychoactive agent 4-bromo-2 5-dimethoxyphenethylamine: a potential drug of abuse Pharmacol. Biochem. Behav. 30 1988 597 601
17. J.M. Halket Derivatives for gas chromatography-mass spectrometry K. Blau J.M. Halket Handbook of Derivatives for Chromatography 1993 John Wiley & Sons Chichester pp. 297-325
18. J.G. Hengstler, M. Arand, M.E. Herrero, and F. Oesch Polymorphisms of N-acetyltransferases, glutathione S-transferases microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility Recent Results Cancer Res. 154 1998 47 85
19. J.G. Hengstler, M.S. Bogdanffy, H.M. Bolt, and F. Oesch Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate Annu. Rev. Pharmacol. Toxicol. 43 2003 485 520
20. J.G. Hengstler, B.V.d. Burg, P. Steinberg, and F. Oesch Interspecies differences in cancer susceptibility and toxicity Drug Metab. Rev. 31 1999 917 970
21. J.G. Hengstler, J. Lange, A. Kett, N. Dornhöfer, R. Meinert, M. Arand, P.G. Knapstein, R. Becker, F. Oesch, and B. Tanner Contribution of c-erbB-2 and topoisomerase IIa to chemoresistance in ovarian cancer Cancer Res. 59 1999 3206 3214
22. J.G. Hengstler, M. Ringel, K. Biefang, S. Hammel, U. Milbert, M. Gerl, M. Klebach, B. Diener, K.L. Platt, T. Böttger, P. Steinberg, and F. Oesch Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction Chem. Biol. Interact. 125 2000 51 73
23. J.G. Hengstler, D. Utesch, P. Steinberg, M. Ringel, N. Swales, K. Biefang, K.L. Platt, B. Diener, T. Böttger, T. Fischer, and F. Oesch Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction Drug Metab. Rev. 32 2000 81 118
24. A.L. Jones, and K.J. Simpson Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications Aliment. Pharmacol. Ther. 13 1999 129 133
25. T. Kanamori, H. Inoue, Y. Iwata, Y. Ohmae, and T. Kishi In vivo metabolism of 4-bromo-2 5-dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites J. Anal. Toxicol. 26 2002 61 66
26. G.J. Kapadia, and M.B. Fayez Peyote constituents: chemistry, biogenesis, and biological effects J. Pharm. Sci. 59 1970 1699 1727
27. M. Katagi, and H. Tsuchihashi Update on clandestine amphetamines and their analogues recently seen in Japan J. Health Sci. 48 2002 14 21
28. A.P. Li, P.D. Gorycki, J.G. Hengstler, G.L. Kedderis, H.G. Koebe, R. Rahmani, G. Sousas, J.M. Silva, and P. Skett Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel Chem. Biol. Interact. 121 1999 117 123
29. M. Lobos, Y. Borges, E. Gonzalez, and B. Cassels The action of the psychoactive drug 2C-B on isolated rat thoracic aorta Gen. Pharmacol. 23 1992 1139 1142
30. A. Malpass, J.M. White, R.J. Irvine, A.A. Somogyi, and F. Bochner Acute toxicity of 3 4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti rats Pharmacol. Biochem. Behav. 64 1999 29 34
31. F. Musshoff Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine Drug Metab. Rev. 32 2000 15 44
32. Z. Pelah, J.M. Wilson, M. Ohashi, H. Budzikiewicz, and C. Djerassi Mass spectrometry in structural and stereochemical problems - XXXIV. Aromatic methyl and ethyl ethers Tetrahedron 19 1963 2233 2240
33. J.F.A. Ragan, S.A. Hite, M.S. Samuels, and R.E. Garey 4-Bromo-2,5-dimethoxyphenethylamine: Identification of a New Street Drug J. Anal. Toxicol. 9 1985 91 93
34. M. Ringel, F. Oesch, A. Bader, M. Gerl, M. Klebach, M. Quint, B. Tanner, W. Dillenburg, T. Böttger, and J.G. Hengstler Permissive and suppressive effects of dexamethasone on enzyme induction in hepatocyte cultures Xenobiotica 32 2002 653 666
35. S. Shiiyama, T. Soejima-Ohkuma, S. Honda, Y. Kumagai, A.K. Cho, H. Yamada, K. Oguri, and H. Yoshimura Major role of the CYP2C isozymes in deamination of amphetamine and benzphetamine: evidence for the quinidine-specific inhibition of the reactions catalysed by rabbit enzyme Xenobiotica 27 1997 379 387
36. P. Steinberg, T. Fischer, S. Kiulies, K. Biefang, K.-L. Platt, F. Oesch, T. Böttger, C. Bulitta, P. Kempf, and J.G. Hengstler Drug metabolizing capacity of cryopreserved human, rat and mouse liver parenchymal cells in suspension Drug Metab. Dispos. 27 1999 1415 1422
37. G.T. Tucker, M.S. Lennard, S.W. Ellis, H.F. Woods, A.K. Cho, L.Y. Lin, A. Hiratsuka, D.A. Schmitz, and T.Y. Chu The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6) Biochem. Pharmacol. 47 1994 1151 1156
38. D. Velea, M. Hautefeuille, G. Vazeille, and C. Lantran-Davoux Nouvelles drogues synthétiques empathogènes L'Encéphale XXV 1999 508 514
39. K. Watanabe, Y. Kayano, T. Matsunaga, I. Yamamoto, and H. Yoshimura 3,4,5-Trimethoxyphenylacetaldehyde, an intermediate metabolite of mescaline, is a substrate for microsomal aldehyde oxygenase in the mouse liver Biol. Pharm. Bull. 18 1995 696 699
40. World Health Organization (WHO), 2001. WHO Expert Committee on Drug Dependence. Thirty-second report. World Health Organ. Tech. Rep. Ser. 903, 1-26.
41. D. Wu, S.V. Otton, T. Inaba, W. Kalow, and E.M. Sellers Interactions of amphetamine analogs with human liver CYP2D6 Biochem. Pharmacol. 53 1997 1605 1612
42. H. Yamada, S. Shiiyama, T. Soejima-Ohkuma, S. Honda, Y. Kumagai, A.K. Cho, K. Oguri, and H. Yoshimura Deamination of amphetamines by cytochromes P450: studies on substrate specificity and regioselectivity with microsomes and purified CYP2C subfamily isozymes J. Toxicol. Sci. 22 1997 65 73
43. J.S. Zwieg, and J.N. Castagnoli Metabolic O-demethylation of the psychotomimetic amine 1-(2 5-dimetroxy-4-methylphenyl)-2-aminopropane Psychopharmacol. Commun. 1 1975 359 371